NIH R01 · 2025
The Mechanism of Sigma 1 Receptor Mediated Neuroprotection in Glaucoma
The long-term goal of our laboratory is to develop successful neuroprotective treatments for glaucoma. Glaucoma is a blinding disease for which neuroprotective treatments are desperately needed. In the visual system, retinal ganglion cells (RGCs) conduct impulses to the visual cortex via RGC axons which form the optic nerve (ON). Loss of RGCs and their axons are the underlying cellular cause of many optic neuropathies including glaucoma. RGC axons are particularly vulnerable to damage at the optic nerve head (ONH) where ONH astrocytes (ONHAs) are the main glial cell. This proposal focuses on sigma-1 receptor (S1R) as a promising therapeutic target in glaucoma. S1R is a ligand operated…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.